Huchuang United Files for IPO: China's Leading 'Smart Reproductive' Solutions Provider Expands into the U.S. Market

According to the previously released "Report on the Current Status of Infertility in China" by the China Population Association, there are over 50 million infertile couples of childbearing age in China, accounting for 12.5%-15% of the childbearing population. Furthermore, influenced by factors such as delayed childbearing age, increased social pressure, and environmental changes, the infertility rate is gradually rising.

In addition to conventional pharmacological and surgical treatments, Assisted Reproductive Technology (ART) is one of the most effective approaches for managing infertility.

According to the “2022 Panorama of China’s Assisted Reproductive Technology Industry” report by Qianzhan Industry Research Institute, the penetration rate of assisted reproductive technology (ART) services in China was still below 10% in 2023, compared with over 30% in developed countries and regions such as Europe and the United States. Behind this vast population of tens of millions of patients lies substantial unmet clinical demand, as well as significant potential for future market growth.

Source: Qianzhan Industry Research Institute

From the supply side, as of June 30, 2022, there were 543 medical institutions in China approved to conduct human assisted reproductive technology (ART). However, compared with the guideline in the “Guiding Principles for the Allocation and Planning of Human Assisted Reproductive Technology,” which stipulates that one ART center should be planned for every 3 million people, there remains a shortage in supply. Furthermore, medical devices used for ART in China are still in the stage of domestic substitution characterized by technological follow-up, requiring further improvement and comprehensive development.

Against this supply-and-demand backdrop, the proprietary products of a medical technology company specializing in comprehensive “smart reproduction” solutions are now used in over 300 reproductive centers across China, capturing more than 50% of the market among Chinese assisted reproductive technology (ART) institutions, with some products having successfully entered the U.S. market. This company is the well-known industry player Wuhan Huchuang Union Technology Co., Ltd. (hereinafter referred to as “Huchuang Union”).

When discussing the origins of the company, Ms. Cui, Marketing Director at Wuhan Huchuang Union Technology Co., LTD, stated,“Wuhan Huchuang Union Technology Co., LTD was officially established in 2016, but in fact, the founding team had already entered the healthcare IT industry before 2010.”

The company’s predecessor was primarily engaged in the development and promotion of medical software, including Hospital Information Systems (HIS), Laboratory Information Systems (LIS), and Picture Archiving and Communication Systems (PACS). Through close collaboration and exchange with healthcare institutions, the founding team keenly recognized that China’s assisted reproductive technology (ART) industry was experiencing rapid growth driven by the rising number of infertile patients. Meanwhile, as the industry advanced swiftly, demands for specialized informatics products became increasingly stringent, with a clear trend toward greater standardization and intelligence.

Therefore, Wuhan Huchuang Union Technology Co., Ltd. was officially established in 2016, focusing on the development and provision of informatized and intelligent products for the assisted reproductive technology (ART) sector. Starting with an ART information management system, the company has maintained a localized approach and gradually developed a range of high-performance, stable-quality software and intelligent hardware solutions tailored to the clinical and laboratory needs of ART. These products are better aligned with China’s specific conditions and the usage habits of Chinese physicians, and the company has obtained multiple medical device registration certificates.

Taking the laboratory safety products for reproductive centers as an example, Ms. Cui introduced to VCBeat that,“Following the market launch of the laboratory safety products co-developed by Wuhan Huchuang Union Technology Co., LTD, their strong competitiveness significantly eroded the market share of imported brands. Leveraging superior performance, high customer stickiness, and the advantages of localized services, Wuhan Huchuang Union rapidly secured the leading position in China’s market share, swiftly achieving domestic substitution for this product category.”

Assisted reproductive technology is a restricted and strictly regulated field, not available in all regions or hospitals. To address the uneven distribution of high-quality medical resources, enable more infertility patients to receive treatment, and improve their chances of conception and quality of life, Wuhan Huchuang Union Technology Co., LTD has leveraged its expertise in medical informatization to developRemote Consultation and Referral Platform for Infertility andPatient Smart Healthcare Service APP - Ai Le Yun, has established an online hospital for infertility and reproductive health to empower reproductive centers, enabling them to reach patients more broadly, directly, and efficiently. This initiative reduces the time and financial burdens associated with patient travel and helps alleviate the challenges faced by patients in remote areas who struggle to access or receive treatment.

In summary, Wuhan Huchuang Union Technology Co., LTD upholds the vision of “enabling more families to conceive healthy offspring.” It is committed to providing users with an integrated “Smart Reproduction” solution that combines “Smart Healthcare,” “Smart Services,” and “Smart Management.” By offering infertility health education, disease prevention, and prognosis management for patients, as well as full-cycle diagnostic and therapeutic products and services for reproductive centers, Wuhan Huchuang Union aims to benefit more families struggling with infertility and help them realize their dream of having children.

After the egg and sperm combine to form a zygote, it must be cultured in vitro for 3 to 6 days before the embryo can be transferred into the uterus. Embryo incubators play a crucial role in assisted reproductive technology by simulating the growth environment of the embryo within the mother’s body. They provide a stable and well-controlled environment to ensure optimal embryonic development, which is essential for improving embryo quality and success rates. Consequently, both the industry and clinical practitioners impose extremely high requirements on the safety, stability, and efficacy of these products.

One of the core hardware products of Wuhan Huchuang Union Technology Co., LTD is the embryo incubator, with a series of products developed through years of research and development. In particular, the time-lapse incubation system newly launched in the past two years is an important product poised to replace traditional embryo incubators in the future.Time-lapse incubators incorporate a built-in optical microscopy imaging system into traditional culture systems, enabling real-time photographic monitoring of embryonic development over 24 hours without removing the embryos from the incubator. This capability is of significant importance for maintaining the stability of the embryonic growth environment and facilitating accurate assessment and selection of embryos by clinicians.

In 2021, Wuhan Huchuang Union Technology Co., LTD obtained the medical device registration certificate for its time-lapse incubator, which features fully independent intellectual property rights, becoming the first manufacturer in China to secure such certification for a time-lapse incubator. The related technology was awarded the Second Prize for Provincial Scientific and Technological Progress.

Building on this foundation, the second-generation time-lapse incubator was rapidly iterated and launched in 2023.

Wuhan Huchuang Union’s time-lapse incubators offer distinct advantages over comparable products. For instance, the company’s information system station software seamlessly integrates with its time-lapse incubators to enable bidirectional transmission of patient treatment data. Functions such as real-time image viewing, embryo annotation, and real-time incubator monitoring can be performed directly within the electronic medical record (EMR) system for assisted reproduction, effectively reducing healthcare professionals’ workload while enhancing data accuracy and operational convenience.

Embryo Development Images Observed Under a Time-Lapse Incubator

Additionally, the AI software NUWA, independently developed by Wuhan Huchuang Union Technology Co., LTD^®It also provides AI-based embryo recognition and assessment services. NUWA^®It can automatically and accurately identify morphological and kinetic parameters of embryos at multiple key developmental stages, including the pronuclear stage, cleavage stage, and blastocyst stage. By leveraging various neural network algorithms and machine learning techniques to build and refine embryo analysis models, it provides embryologists with more detailed criteria for selecting embryos with greater developmental potential.

VCBeat also learned during the interview that, from early 2021 when the certificate was obtained toToday, Huchuang’s time-lapse incubators have achieved strong sales performance in China and received widespread acclaim from users, thanks to their superior functionality, performance, and positive user reputation.

In the domestic market, China’s assisted reproductive technology (ART) market has officially entered a new era of “insurance coverage.” In 2023, the Beijing Municipal Healthcare Security Administration issued a notice to include 16 therapeutic ART procedures in Beijing’s basic medical insurance scheme, with outpatient reimbursement covered under Category A. Furthermore, healthcare security administrations and commercial insurers in provinces and cities such as Hangzhou, Jingmen, and Liaoning have subsequently introduced specific plans for ART coverage.

Driven by national policies, Wuhan Huchuang Union Technology Co., LTD’s “Smart Reproduction” holistic solution has provided scientifically standardized business processing, data analytics, and decision support to over 300 reproductive centers across China. While several of its products already lead the domestic market in terms of market share, the company still holds significant growth potential in the Chinese market, given the favorable policy environment and current under-penetration.

Established for nearly a decade and deeply engaged in the field of assisted reproduction for almost twenty years, Wuhan Huchuang Union Technology Co., LTD has gained market and social recognition on multiple levels, emerging as an advocate and pioneer of smart reproductive healthcare in China. For example,Wuhan Huchuang Union Technology Co., LTD is an investee of the Ministry of Science and Technology’s Innovation Fund for Technology-Based SMEs and the Hubei Provincial High-Tech Industry Investment Fund. The company has also been recognized as a Hubei Provincial High-Tech Enterprise, a Hubei Provincial “Specialized, Refined, Differential, and Innovative” (SRDI) Enterprise, a participant in the Wuhan East Lake High-Tech Development Zone 3551 Talent Program, and a Gazelle Enterprise in the Wuhan East Lake High-Tech Development Zone.

Riding the waves of the times and policy trends, “going global” has become an imperative question for leading Chinese medical enterprises to answer, as well as a necessary path for their growth and expansion. In response, Wuhan Huchuang Union Technology Co., LTD is also actively exploring overseas markets.

Ms. Cui stated, “After achieving a leading position in the Chinese market, Wuhan Huchuang Union Technology Co., LTD has targeted international expansion, selecting the more mature and highly competitive U.S. assisted reproductive technology (ART) market as its initial overseas launch destination.” Currently, five of the company’s products have obtained FDA registration, FCC certification, and EU CE marking, and are already in use at multiple fertility centers across the United States.

Furthermore, in October 2023, Wuhan Huchuang Union Technology Co., LTD was once again invited to exhibit at the American Society for Reproductive Medicine (ASRM) annual meeting, one of the largest and most influential international conferences in the field of reproductive medicine. On this global stage, the company comprehensively showcased its “Smart Reproduction” solutions and the innovative strength of intelligent manufacturing in China.

2023 American Society for Reproductive Medicine – Wuhan Huchuang Union Joint Booth

Speaking of the future, Ms. Cui said,“The U.S. market not only imposes extremely high requirements on product technical quality and services, but also presents higher competitive barriers as a mature market. Currently, Wuhan Huchuang Union Technology Co., LTD has successfully broken into the U.S. market. In the future, leveraging high-quality American users and the premium U.S. market as a starting point, the company will continuously expand its international influence, rapidly build global service capabilities, and gradually extend its reach to Europe, Southeast Asia, and other regions, bringing Chinese innovative technologies and services to a broader global stage.”